1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2020, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.
Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 25, 189, 202, 3, 21, 285, 50 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 17, 15, 54 and 11 molecules, respectively.
Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Ovarian Cancer - Overview
- Ovarian Cancer - Therapeutics Development
- Ovarian Cancer - Therapeutics Assessment
- Ovarian Cancer - Companies Involved in Therapeutics Development
- Ovarian Cancer - Drug Profiles
- Ovarian Cancer - Dormant Projects
- Ovarian Cancer - Discontinued Products
- Ovarian Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Ovarian Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
- Ovarian Cancer - Pipeline by 4D Pharma Plc, H1 2020
- Ovarian Cancer - Pipeline by 4SC AG, H1 2020
- Ovarian Cancer - Pipeline by Aadi Bioscience Inc, H1 2020
- Ovarian Cancer - Pipeline by AB Science SA, H1 2020
- Ovarian Cancer - Pipeline by AbbVie Inc, H1 2020
- Ovarian Cancer - Pipeline by AbClon Inc, H1 2020
- Ovarian Cancer - Pipeline by Abion Inc, H1 2020
- Ovarian Cancer - Pipeline by ABL Bio Inc, H1 2020
- Ovarian Cancer - Pipeline by ABM Therapeutics Inc, H1 2020
- Ovarian Cancer - Pipeline by Acepodia Biotech Inc, H1 2020
- Ovarian Cancer - Pipeline by Acrotech Biopharma LLC, H1 2020
- Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
- Ovarian Cancer - Pipeline by Adare Pharmaceuticals Inc, H1 2020
- Ovarian Cancer - Pipeline by ADC Therapeutics SA, H1 2020
- Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2020
- Ovarian Cancer - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
- Ovarian Cancer - Pipeline by ADRx Inc, H1 2020
- Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2020
- Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
- Ovarian Cancer - Pipeline by Adze Biotechnology Inc, H1 2020
- Ovarian Cancer - Pipeline by Affimed GmbH, H1 2020
- Ovarian Cancer - Pipeline by Affina Biotechnologies Inc, H1 2020
- Ovarian Cancer - Pipeline by Agency for Science, Technology and Research, H1 2020
- Ovarian Cancer - Pipeline by Agenus Inc, H1 2020
List of Figures
- Number of Products under Development for Ovarian Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma Plc
- 4SC AG
- Aadi Bioscience Inc
- AB Science SA
- AbbVie Inc
- AbClon Inc
- Abion Inc
- ABL Bio Inc
- ABM Therapeutics Inc
- Acepodia Biotech Inc
- Acrotech Biopharma LLC
- Adaptimmune Therapeutics Plc
- Adare Pharmaceuticals Inc
- ADC Therapeutics SA
- Adgero Biopharmaceuticals Holdings Inc
- Adlai Nortye Biopharma Co Ltd
- ADRx Inc
- Advanced Cancer Therapeutics LLC
- Advenchen Laboratories LLC
- Adze Biotechnology Inc
- Affimed GmbH
- Affina Biotechnologies Inc
- Agency for Science, Technology and Research
- Agenus Inc
- AIM ImmunoTech Inc
- AiVita Biomedical Inc
- Aldeyra Therapeutics Inc
- Alfasigma SpA
- Alkermes Plc
- Allife Medical Science and Technology Co Ltd
- Alligator Bioscience AB
- Allist Shanghai Pharmaceutical Technology Co Ltd
- Almac Discovery Ltd
- Alteogen Inc
- ALX Oncology Inc
- Ambrx Inc
- Amgen Inc
- Amplia Therapeutics Ltd
- Anew Oncology Inc
- AnGes Inc
- Angex Pharmaceutical Inc
- Anixa Biosciences Inc
- ANP Technologies Inc
- AntiCancer Inc
- Anwita Biosciences Inc
- AP Biosciences Inc
- Apexian Pharmaceuticals Inc
- Apexigen Inc
- Aphios Corp
- Apollomics Inc
- Apotex Inc
- Aprea Therapeutics AB
- Aprogen Inc
- Aravive Inc
- Arch Oncology Inc
- Arcus Biosciences Inc
- Argenx SE
- Arrien Pharmaceuticals LLC
- Asana BioSciences LLC
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Aslan Pharmaceuticals Ltd
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Athenex Inc
- Atreca Inc
- Atrin Pharmaceuticals LLC
- Aurigene Discovery Technologies Ltd
- Avicanna Inc
- Basilea Pharmaceutica Ltd
- Bavarian Nordic A/S
- Bayer AG
- BBS NanoTechnology Ltd
- BeiGene Ltd
- Beijing Fogangren Bio-Pharm Tech Co Ltd
- Beijing Foreland Pharma Co Ltd
- Beijing Neoantigen Biotechnology Co Ltd
- Bicycle Therapeutics Plc
- Bio-Path Holdings Inc
- Bio-Thera Solutions Ltd
- BioAtla LLC
- BIOCND Inc
- BioEclipse Therapeutics Inc
- BioIntegrator Ltd
- Biokine Therapeutics Ltd
- BioMed Valley Discoveries Inc
- BioMoti Ltd
- BioNTech SE
- BioVaxys LLC
- bluebird bio Inc
- Boehringer Ingelheim International GmbH
- Boston Biomedical Inc
- Bristol-Myers Squibb Co
- Byondis BV
- Canget BioTekpharma LLC
- Cardiff Oncology Inc
- Carisma Therapeutics Inc
- Carlina Technologies SAS
- CaroGen Corp
- Carrick Therapeutics Ltd
- Carrick Therapeutics UK Ltd
- Cartherics Pty Ltd
- CAS-Lamvac Biotech Co Ltd
- Cellatoz Therapeutics Inc
- Celldex Therapeutics Inc
- Celleron Therapeutics Ltd
- Cellestia Biotech AG
- Cello Therapeutics Inc
- Celprogen Inc
- Celsion Corp
- Celtec Inc
- Celyad Oncology
- Centurion BioPharma Corp
- CerRx Inc
- CG Oncology Inc
- CHA Biotech Co Ltd
- Checkmate Pharmaceuticals Inc
- Chipscreen Biosciences Ltd
- Chongqing Pharmaceutical Research Institute Co Ltd
- Clarity Pharmaceuticals Pty Ltd
- Claudin Technologies LLC
- Clayton Biotechnologies Inc
- Cloaked Therapeutics LLC
- Clovis Oncology Inc
- CMG Pharmaceutical Co Ltd
- CNS Pharmaceuticals Inc
- CohBar Inc
- Coherent Biopharma
- Commence Bio Inc
- Compugen Ltd
- Context Therapeutics LLC
- Convert Pharmaceuticals SA
- Corcept Therapeutics Inc
- Cotinga Pharmaceuticals Inc
- Cristal Therapeutics BV
- Cue Biopharma Inc
- CureLab Oncology Inc
- Curis Inc
- Cyclacel Pharmaceuticals Inc
- Cynvec LLC
- Cyteir Therapeutics Inc
- Cytocom Inc
- Cytodyn Inc
- CZ BioMed Corp
- DAE HWA Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- DC Prime BV
- Deciphera Pharmaceuticals Inc
- DEKK-TEC Inc
- DelMar Pharmaceuticals Inc
- Delta-Fly Pharma Inc
- DevaCell Inc
- Disulfican Ltd
- Dongkook Pharmaceutical Co Ltd
- Dophen Biomed Inc
- Dr. Reddy's Laboratories Ltd
- Ecrins Therapeutics SAS
- EirGenix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Elicio Therapeutics
- Ellipses Pharma Ltd
- Elthera AG
- Elucida Oncology Inc
- ENB Therapeutics LLC
- EntreChem SL
- EpicentRx Inc
- Epigen Biosciences Inc
- Epigene Therapeutics Inc
- Epizyme Inc
- Epsilogen Ltd
- Epygen Biotech Pvt Ltd
- Ervaxx Ltd
- Esperance Pharmaceuticals Inc
- Esperas Pharma Inc
- Essential Biotechnology LLC
- Eureka Therapeutics Inc
- Evestra Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Falcon Therapeutics Inc
- Faron Pharmaceuticals Oy
- Fate Therapeutics Inc
- For-Robin Inc
- Fujifilm Holdings Corp
- GAiA BioMedicine Inc
- GamaMabs Pharma SA
- Gene Techno Science Co Ltd
- Genekey Biotech Chengdu Co Ltd
- Genelux Corp
- Genentech Inc
- Geneos Therapeutics Inc
- Genisphere LLC
- Genmab AS
- GeoVax Labs Inc
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- GLG Pharma SA
- Glycomantra Inc
- GlycoNex Inc
- Glysantis Inc
- Gmax Biopharm Ltd
- GO Therapeutics Inc
- GP Pharm SA
- Gracell Biotechnology Ltd
- Gradalis Inc
- GT Biopharma Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Guangzhou Hanghua Bio Pharmaceutical Technology Co
- Hangzhou Neoantigen Therapeutics Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
